The management of dilated cardiomyopathy(DCM) is well established. However, a subset of patients does not have recovery from or have recurrences of left ventricular(LV) dysfunction despite receiving optimal medical therapy. Coronary microvascular dysfunction(CMD) can result from structural and functional abnormalities at the intramural and small coronary vessel level affecting coronary blood flow autoregulation and consequently leading to impaired coronary flow reserve. Dilated myocardial phenotype may be responsible for CMD in DCM. Anisodamine can exert a significant effect on relieving microvascular spasm, and improving and dredging the coronary microcirculation. However,whether CMD can be potentially improved with anisodamine to make DCM better remains incompletely understood.